MannKind Co. (NASDAQ:MNKD) Shares Purchased by Walleye Capital LLC

Walleye Capital LLC raised its position in MannKind Co. (NASDAQ:MNKD) by 5.0% during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 818,602 shares of the biopharmaceutical company’s stock after purchasing an additional 39,145 shares during the period. Walleye Capital LLC’s holdings in MannKind were worth $5,149,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in MNKD. Millennium Management LLC lifted its holdings in shares of MannKind by 189.8% during the 2nd quarter. Millennium Management LLC now owns 4,744,519 shares of the biopharmaceutical company’s stock worth $24,766,000 after acquiring an additional 3,107,598 shares during the period. TSP Capital Management Group LLC grew its position in MannKind by 196.0% in the second quarter. TSP Capital Management Group LLC now owns 2,391,900 shares of the biopharmaceutical company’s stock valued at $12,486,000 after acquiring an additional 1,583,800 shares in the last quarter. Charles Schwab Investment Management Inc. grew its position in MannKind by 1.9% in the third quarter. Charles Schwab Investment Management Inc. now owns 2,224,829 shares of the biopharmaceutical company’s stock valued at $13,994,000 after acquiring an additional 42,041 shares in the last quarter. 180 Wealth Advisors LLC grew its position in MannKind by 4.7% in the second quarter. 180 Wealth Advisors LLC now owns 2,034,134 shares of the biopharmaceutical company’s stock valued at $11,411,000 after acquiring an additional 91,924 shares in the last quarter. Finally, Connor Clark & Lunn Investment Management Ltd. grew its position in shares of MannKind by 15.4% during the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 1,885,370 shares of the biopharmaceutical company’s stock worth $11,859,000 after buying an additional 251,587 shares in the last quarter. 49.55% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of research firms have recently weighed in on MNKD. StockNews.com raised shares of MannKind from a “hold” rating to a “buy” rating in a research report on Friday. Leerink Partners initiated coverage on MannKind in a research note on Monday, September 9th. They issued an “outperform” rating and a $8.00 target price on the stock. Leerink Partnrs upgraded shares of MannKind to a “strong-buy” rating in a research note on Monday, September 9th. Finally, Oppenheimer lifted their price objective on shares of MannKind from $10.00 to $12.00 and gave the company an “outperform” rating in a research note on Wednesday, August 28th. Seven investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Buy” and a consensus target price of $8.67.

MannKind Trading Up 2.6 %

Shares of MNKD opened at $6.78 on Monday. The business’s 50-day moving average price is $6.71 and its 200 day moving average price is $5.84. The stock has a market capitalization of $1.87 billion, a P/E ratio of 96.86 and a beta of 1.30. MannKind Co. has a 1-year low of $3.17 and a 1-year high of $7.63.

Insider Buying and Selling

In other news, Director Steven B. Binder sold 67,536 shares of MannKind stock in a transaction dated Friday, November 22nd. The stock was sold at an average price of $6.89, for a total transaction of $465,323.04. Following the completion of the sale, the director now directly owns 1,075,026 shares in the company, valued at $7,406,929.14. The trade was a 5.91 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Stuart A. Tross sold 25,000 shares of MannKind stock in a transaction dated Tuesday, September 3rd. The shares were sold at an average price of $6.26, for a total value of $156,500.00. Following the sale, the insider now owns 1,022,191 shares of the company’s stock, valued at approximately $6,398,915.66. This represents a 2.39 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders have sold 215,075 shares of company stock valued at $1,482,087. 3.00% of the stock is owned by corporate insiders.

About MannKind

MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults.